ArticleClinical and experimental immunology2003
Validation of the interleukin-10 knockout mouse model of colitis: antitumour necrosis factor-antibodies suppress the progression of colitis.
Article in Clinical and experimental immunology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Effects of Prebiotic Dietary Fibers, Probiotics, and Synbiotics on Gut Permeability and Immunity: A Systematic Review.Iranian journal of medical sciences · 2025Pooled it
- Trial
- From AI-AssistedPharmaceuticals (Basel, Switzerland) · 2025Review
- Evaluation of oxidative stress in an experimental model of Crohn's disease treated with hyperbaric oxygen therapy.Clinics (Sao Paulo, Brazil) · 2023Article
- Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-deficient Mouse Model.Journal of visualized experiments : JoVE · 2022Article
- Molecular mechanism of the TGF‑β/Smad7 signaling pathway in ulcerative colitis.Molecular medicine reports · 2022Article
- Dysregulated hepatic UDP-glucuronosyltransferases and flavonoids glucuronidation in experimental colitis.Frontiers in pharmacology · 2022Article
- Deep learning-based approach to the characterization and quantification of histopathology in mouse models of colitis.PloS one · 2022Article
- E-cadherin activating antibodies limit barrier dysfunction and inflammation in mouse inflammatory bowel disease.Tissue barriers · 2021Article
- T cell plasticity in renal autoimmune disease.Cell and tissue research · 2021Review
- Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution.Science advances · 2021Article
- Probiotic lactobacilli as a promising strategy to ameliorate disorders associated with intestinal inflammation induced by a non-steroidal anti-inflammatory drug.Scientific reports · 2021Article
- Review
- PIR-B Regulates CD4Cellular and molecular gastroenterology and hepatology · 2021Article
- Mouse Models of Intestinal Fibrosis.Methods in molecular biology (Clifton, N.J.) · 2021Article
- TNF Receptor 1 Promotes Early-Life Immunity and Protects against Colitis in Mice.Cell reports · 2020Article
- Heparin-Coated Albumin Nanoparticles for Drug Combination in Targeting Inflamed Intestine.Advanced healthcare materials · 2020Article
- Optimizing infrared spectral discrimination to enhance disease diagnostics: monitoring the signatures of inflammatory bowel diseases with anti-TNFα therapy.Biomedical optics express · 2020Article
- Ion Transport Basis of Diarrhea in a Mouse Model of Adoptive T Cell Transfer Colitis.Digestive diseases and sciences · 2020Article
- Mucins in Intestinal Mucosal Defense and Inflammation: Learning From Clinical and Experimental Studies.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in understanding pathogenesis and developing new therapies are hastened by the use of effective animal models of disease. In inflammatory bowel disease, such as Crohn's disease, a variety of models have been used, including the IL-10 knockout mouse. However, in order to be truly valuable, the models need to respond to existing therapy in a way which resembles the human disease. In the light of recent developments, in which refractory Crohn's disease responds well to anti-TNF antibody therapy, we set out to validate the IL-10 knockout model of Crohn's disease by examining its response to anti-TNF therapy. We developed a new scoring system for IL-10 knockout mice, similar to the Crohn's Disease Activity Index in humans, analysed stool samples for cytokines and compared the findings with histology. We found that anti-TNF antibody therapy starting at 4 weeks markedly ameliorated the disease, as judged by the clinical score or by histological analysis of the gut. Furthermore, analysis of stool samples for cytokines revealed a marked diminution of inflammatory cytokines, adding a further accurate measure of the improvement. This model may thus be useful for evaluating other therapeutic modalities of relevance to Crohn's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.